APRE · Aprea Therapeutics, Inc.
$0.64
+0.03 (+4.25%)
At close · Jul 29
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed May 13, 2026
Market Cap
$7.60M
Shares
12.38M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.61
Open$0.67
Day$0.60–0.67
52W$0.55–2.00
Avg vol 30d85K
Short int61K · 0.5% float · 1.0d
Short vol13%
Last earningsMay 16, 2022
DataJan 2020–Jul 2026
Filing10-Q · May 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−33%
below
Price vs 50-day avg
−21%
below
RSI (14)
32
neutral
MACD trend
Negative
52-week position
5%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−22%
trailing
6-month return
−18%
trailing
YTD return
−28%
this year
Relative strength
−26%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 22 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.49% of float · ▼ -22.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
22 holders — mid 3-yr range
Squeeze score
28
low risk · 0–100
Fundamentals
EPS growth
+18%
Y/Y
Free cash flow
$-12.9M
Balance sheet
$14.6M
net cash
Quant / Vol
risk profile
Volatility
87%
annualized · 1-yr
Max drawdown
−69%
past year
ATR
10.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−33%
Bearish
Price vs 50-day avg
−21%
Bearish
RSI (14)
32
Neutral
MACD trend
Negative
Bearish
52-week position
5%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 22 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.49% of float · ▼ -22.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
22 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 5%
52-wk high $2
vs 200-day avg -33%
vs 50-day avg -21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
APRE
this stock
Aprea Therapeutics, Inc.
|
$7.60M | -28.1% | — | — | 0.5% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| APRE | -8.3% | -22.3% | -18.3% | -23.5% | -28.1% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -7.3% | -22.3% | -25.7% | -22.7% | -36.7% |